MoonLake (MLTX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-143.1M
Net Income
-121.2M
EPS (Diluted)
-$1.89
Balance Sheet Metrics
Total Assets
477.9M
Total Liabilities
24.5M
Shareholders Equity
453.4M
Debt to Equity
0.05
Cash Flow Metrics
Operating Cash Flow
-116.0M
Free Cash Flow
-117.1M
Revenue & Profitability Trend
MoonLake Income Statement From 2022 to 2024
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 143.1M | 54.1M | 65.1M |
| Operating Income | -143.1M | -54.1M | -65.1M |
| Pre-tax Income | -121.0M | -44.0M | -64.5M |
| Income Tax | 282.2K | 94.4K | 36.4K |
| Net Income | -121.2M | -44.1M | -64.5M |
| EPS (Diluted) | -$1.89 | -$0.73 | -$1.70 |
Income Statement Trend
MoonLake Balance Sheet From 2021 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | 474.3M | 514.2M | 76.5M | 9.6M |
| Non-Current Assets | 3.6M | 12.4M | 332.0K | 45.7K |
| Total Assets | 477.9M | 526.5M | 76.8M | 9.7M |
| Liabilities | ||||
| Current Liabilities | 22.5M | 10.0M | 7.7M | 21.1M |
| Non-Current Liabilities | 2.1M | 3.1M | 411.2K | 239.9K |
| Total Liabilities | 24.5M | 13.0M | 8.1M | 21.3M |
| Equity | ||||
| Total Shareholders Equity | 453.4M | 513.5M | 68.8M | -11.6M |
Balance Sheet Composition
MoonLake Cash Flow Statement From 2022 to 2024
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -121.2M | -44.1M | -64.5M |
| Operating Cash Flow | -116.0M | -37.7M | -54.8M |
| Investing Activities | |||
| Capital Expenditures | -519.5K | -284.6K | -16.0K |
| Investing Cash Flow | -205.6M | -25.2M | -32.3M |
| Financing Activities | |||
| Dividends Paid | - | - | - |
| Financing Cash Flow | 51.1M | 479.7M | 119.7M |
| Free Cash Flow | -117.1M | -43.1M | -55.9M |
Cash Flow Trend
MoonLake Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-24.21
Forward P/E
-17.33
Price to Book
6.78
PEG Ratio
-17.33
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-30.64%
Return on Assets
-19.85%
Financial Health
Current Ratio
21.11
Debt to Equity
18.32
Beta
1.23
Per Share Data
EPS (TTM)
-$2.30
Book Value per Share
$6.42
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| mltx | 2.8B | -24.21 | 6.78 | -30.64% | 0.00% | 18.32 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.